Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,894 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Older Adult Clear all
Completed Phase 2 Interventional Results available

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

NCT00456261
View directory record Official record
Conditions
Lung Cancer
Interventions
Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
70 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

NCT06290102
View directory record Official record
Conditions
Asthma
Interventions
TEV-56248, Fp MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Mobile, Alabama • Long Beach, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

NCT05630066
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Alogabat
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

NCT01673451
View directory record Official record
Conditions
CNS
Interventions
E2006, Placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Culver City, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 24, 2026, 2:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults

NCT00183729
View directory record Official record
Conditions
Depression
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Eric Lenze
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 24, 2026, 2:02 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Virtual Reality and Occupational Performance, Satisfaction, and Quality of Life of Older Adults

NCT03784053
View directory record Official record
Conditions
Aging
Interventions
Immersive virtual reality
Other
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 24, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BM Characterization Pilot

NCT03138057
View directory record Official record
Conditions
Diaper Rash
Interventions
Not listed
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
Up to 12 Months
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 24, 2026, 2:02 AM EDT
Terminated Phase 2 Interventional Results available

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00673153
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
Interventions
gemtuzumab ozogamicin, vorinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
4
States / cities
Stanford, California • Detroit, Michigan • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Not applicable Interventional

Effects of Exercise on Markers of Inflammation in Skeletal Muscle in Elderly Hip Fracture Patients

NCT00006194
View directory record Official record
Conditions
Hip Fractures, Muscular Atrophy
Interventions
Exercise
Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

NCT01050257
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir IV, Oseltamivir Oral
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 24, 2026, 2:02 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

MTOR Inhibitors in Older Adults

NCT06727305
View directory record Official record
Conditions
Aging
Interventions
Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet, Everolimus 0.5 MG Oral Tablet, Everolimus 1 MG Oral Tablet, Everolimus 2 MG Oral Tablet
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

NCT02170012
View directory record Official record
Conditions
Healthy Elderly
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Not applicable Interventional Results available

Body Mind Training Project

NCT01564394
View directory record Official record
Conditions
Cancer Related Fatigue
Interventions
Qigong, Non-aerobic stretching
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
55 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Not applicable Interventional Results available

Tolerability and Efficacy of Depakote-extended Release in the Elderly

NCT00318929
View directory record Official record
Conditions
Elderly, Epilepsy, Seizures
Interventions
Divalproex Sodium Extended-Release Tablets
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 24, 2026, 2:02 AM EDT
Recruiting Phase 3 Interventional

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

NCT03588975
View directory record Official record
Conditions
Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Interventions
MACI, microfracture
Biological · Procedure
Lead sponsor
Vericel Corporation
Industry
Eligibility
10 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
14
States / cities
Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Not applicable Interventional

Medication Empowerment and Deprescription for Safety (MEDS) Study

NCT04612166
View directory record Official record
Conditions
Aging, Fall Injury
Interventions
Medication Action Plan and Patient Empowerment (MAP-PE )
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
60 Years to 110 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Clive, Iowa
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Withdrawn Phase 3 Interventional

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

NCT03532022
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, Standard Care
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Vitamin D and Arterial Stiffness in Elderly

NCT03649802
View directory record Official record
Conditions
Vitamin D Deficiency, Arterial Stiffness
Interventions
Low dose vitamin D3, High dose vitamin D3
Dietary Supplement
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
65 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

NCT00023777
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
98
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 24, 2026, 2:02 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

NCT00375557
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions
Divalproex ER, Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heat Wrap Device Safety With Age and Body Fat

NCT01355653
View directory record Official record
Conditions
Back Pain
Interventions
thermal therapy, ThermaCare heatwrap
Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 84 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 24, 2026, 2:02 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Cardiorespiratory Fitness and Acute High-Intensity Exercise Effects on Brain and Cognitive Function in Older Adults

NCT07727577
View directory record Official record
Conditions
Healthy Aging, Cognitive Benefits, Cardio Respiratory Fitness, Brain Activity
Interventions
High-Intensity Interval Training
Behavioral
Lead sponsor
Colby-Sawyer College
Other
Eligibility
55 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New London, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

NCT06106022
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Hollywood, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 24, 2026, 2:02 AM EDT